Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Bullish +65

Elevance Health Q2 Earnings Call Highlights - Defense World

AI-generated analysis

πŸ“ˆ Elevance Health raised its 2026 adjusted diluted EPS outlook to at least $27, citing favorable benefit expense performance and disciplined cost management.

πŸ’° The company expects to return to at least 12% adjusted EPS growth in 2027 off the higher baseline of $26.

πŸ₯ Medicaid operating margin outlook remains at approximately negative 1.75%, with exits planned for D.C. and other unsustainable markets over the next 12-18 months.

πŸ“Š Medicare Advantage results were stronger than expected, driving portfolio repositioning toward dual-eligible special needs plans and HMO products.

πŸ‘₯ Individual ACA member retention is modestly ahead of expectations, with a projected total of at least 1 million members by end of 2026.

πŸ’Ό Commercial health benefits saw a record year in national accounts for 2026 with a nearly as large pipeline for 2027.

πŸš€ Carelon's CareBridge home-care model is being expanded into new markets to generate mid-teens medical savings for members.

πŸ’΅ Second-quarter operating cash flow reached $1.9 billion, prompting a raised full-year outlook of at least $6 billion.

βš–οΈ Elevance received written confirmation from CMS that sanctions will not be imposed regarding a prior matter, closing the issue as of July 9.

πŸ”§ The company plans to use a net below-the-line benefit of $0.80 per share for one-time investments in cost management and AI-enabled tools.

Bullish Signals
  • Elevance Health raised its 2026 adjusted diluted EPS outlook to at least $27, driven by favorable benefit expense performance and disciplined cost management.
  • The company expects to return to at least 12% adjusted EPS growth in 2027 off the higher baseline of $26.
  • Medicare Advantage results were stronger than expected, contributing to quarterly outperformance as the portfolio repositions toward dual-eligible special needs plans and HMO products.
  • Individual ACA member retention is modestly ahead of expectations, with a projected total of at least 1 million members by end of 2026.
  • Commercial health benefits saw a record year in national accounts for 2026 with a nearly as large pipeline for 2027.
  • Carelon's behavioral health programs have delivered average cost savings of 10% through stronger member engagement and fewer adverse events.
  • Second-quarter operating cash flow reached $1.9 billion, prompting a raised full-year outlook of at least $6 billion.
  • Elevance received written confirmation from CMS that sanctions will not be imposed regarding a prior matter, closing the issue as of July 9.
Risk Factors
  • Medicaid operating margin outlook remains at approximately negative 1.75%, with cost drivers remaining elevated in behavioral health and specialty pharmacy.
  • The company plans to exit the District of Columbia Medicaid market and intends to withdraw from additional markets over the next 12-18 months where sustainable performance is not viable.
  • Days in claims payable increased to 45.4 days as of June 30, up 2.9 days from a year earlier, though management maintains confidence in reserving levels.
Full Analysis
Elevance Health (NYSE:ELV) raised its 2026 adjusted earnings outlook following second-quarter results that exceeded management expectations. CEO Gail Boudreaux stated the company now expects 2026 adjusted diluted EPS of at least $27, up from a previous baseline of $26. The company cited favorable benefit expense performance and disciplined cost management as key drivers, with confidence in returning to at least 12% adjusted EPS growth in 2027. Management addressed ongoing challenges in the Medicaid segment, maintaining a full-year operating margin outlook of approximately negative 1.75%. While rate updates were stronger than anticipated, executives noted that cost drivers remain elevated in behavioral health and specialty pharmacy. The company confirmed it will exit the District of Columbia Medicaid market and plans to withdraw from additional markets over the next 12 to 18 months where sustainable performance is not viable. Performance in Medicare Advantage was stronger than expected, contributing to quarterly outperformance as the company repositions its portfolio toward dual-eligible special needs plans and HMO products. Elevance remains on track for at least a 2% operating margin in this segment for 2026. In the individual ACA business, member retention is ahead of expectations, with the company projecting at least 1 million members by year-end. Commercial health benefits performance aligned with expectations, highlighted by a record year in national accounts for 2026 and a robust pipeline for 2027. Carelon's growth strategy continues to focus on home-based care via CareBridge and behavioral health programs that have delivered average cost savings of 10%. The company reported second-quarter operating cash flow of $1.9 billion and raised its full-year outlook to at least $6 billion.